You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥(01672.HK):新冠口服雙前藥ASC10生產成本顯着下降
阿思達克 03-16 09:30
歌禮制藥(01672.HK)宣佈,基於系列優化措施,旗下抗新型冠狀病毒肺炎(COVID-19)口服雙前藥ASC10生產成本顯着下降,目前已拓展ASC10原料藥中間體和其它物料供應商。 公司表示,目前已完成ASC10原料藥關鍵中間體的合成工藝優化,採用生物(酉每)催化綠色合成法有助提升關鍵中間體的合成收率,並降低有機溶劑的使用量。現時歌禮制藥已完成ASC10關鍵生產設備利用率整體提升方案制定;完成連續化生產模式方案制定,旨在提升ASC10製劑的生產收率。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account